 | | Vol. 25.07 – 18 March, 2024 |
| |
|
|
| Investigators conducted an international multicenter Phase II clinical trial testing the hypothesis that non-myeloablative related haploidentical bone marrow transplant with thiotepa and post-transplant cyclophosphamide will result in two-year event-free survival of at least 80%.
[Blood] |
|  |
|
|
| PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| The authors describe a human liver chimeric transgene-free Il2rg−/−/Rag2−/−/Fah−/−/Aavr−/− mouse model overcoming this translational roadblock, by combining liver humanization with AAV receptor ablation, rendering murine cells impermissive to AAV transduction.
[Nature Communications] |
|
|
|
| Scientists presented a scaffold that facilitated the localized administration of the transforming growth factor β gene in the proximal region to accelerate nerve regeneration, while simultaneously delivering nicotinamide mononucleotide adenylyltransferase 2 to the distal region to mitigate Wallerian degeneration.
[Advanced Science] |
|
|
|
| Investigators described a programmable hydrogel adjuvant for personalized immunotherapy after surgical resection. By filling the hydrogel in the cavity, this system addressed the limited secretion of granzyme B during immunotherapy and improved the low immunotherapy responses typically observed.
[Journal Of The American Chemical Society] |
|
|
|
| Deformable smart DNA nanomachines were developed for synergistic intracellular cancer-related miRNAs imaging and chemo-gene therapy of drug-resistant tumors.
[Small] |
|
|
|
| Dog models of multiple sclerosis received either a single treatment of stem cells or a single treatment of exosomes intrathecally and the treatment process was evaluated clinically, radiologically, histopathologically, and electron microscopy and cerebrospinal fluid analysis.
[Proceedings Of The National Academy Of Sciences Of The United States Of America] |
|
|
|
| The authors evaluated the value of fluorodeoxyglucose positron emission tomography/computed tomography (PET/CT) combining with clinical indices and laboratory indicators in predicting outcomes and toxicity of anti-CD19 CAR T cell therapy for diffuse large B cell lymphoma patients.
[European Journal Of Nuclear Medicine And Molecular Imaging] |
|
|
|
| Investigators analyzed the outcome of rabbit anti-thymocyte globulin vs. post-transplantation cyclophosphamide prophylaxis in adult patients with hematologic malignancies undergoing first peripheral blood allogeneic stem cell transplantations from mismatched unrelated donors.
[Blood Cancer Journal] |
|
|
|
| To evaluate the therapeutic effects of combination cells, acute spinal cord injury mice model were established. and combined transplantation of hiPSC-neural stem cells and human mesenchymal stem cells into the lesion site immediately after the injury.
[Current Stem Cell Research & Therapy] |
|
|
|
|
| Unlike other immunotherapy modalities, T cell-based adoptive cell therapy involves directly transferring engineered T cells into patients to eradicate diseased cells; hence, it necessitates methods for effectively activating and expanding T cells in vitro.
[ACS Nano] |
|
|
|
| Hypoxia-induced necrosis and delayed revascularization attenuate organoid viability and functional capacity, alleviated by the integration of diverse cell types e.g., human amniotic epithelial cells and human umbilical vein endothelial cells to boost vascularization.
[Life Sciences] |
|
|
|
| Investigators discuss the clinical characteristics of ischemic bowel disease, analyze the characteristics of human umbilical cord blood mononuclear cells, and use its to treat ischaemic bowel disease.
[Scientific Reports] |
|
|
|
|
| In November, the FDA released an announcement saying it was investigating reports of secondary cancers in people with blood cancers who were treated with CAR T cells.
[Forbes] |
|
|
|
| BioCardia, Inc. announced Centers for Medicare & Medicaid Services approval for reimbursement coverage of the confirmatory Phase III clinical trial of CardiAMP autologous cell therapy for the treatment of patients with ischemic heart failure.
[BioCardia, Inc.] |
|
|
|
|
| April 24 – 26, 2024
Vienna, Austria |
|
|
|
|
|
| | University of California, Davis – Sacramento, California, United States |
|
|
|
| | Takeda – Boston, Massachusetts, United States |
|
|
|
| | University of Sydney – Sydney, Australia |
|
|
|
| | UC Davis – Davis, California, United States |
|
|
|
| | BC Provincial Health Services Authority – Vancouver, British Columbia, Canada/p> |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
